XBI - Agios: Approved Product Upcoming Catalysts
- Mitapivat got approved for PK deficiency.
- They have multiple label expansion potential.
- Current prices are attractively low.
For further details see:
Agios: Approved Product, Upcoming CatalystsLink your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Stock Information
| Company Name: | SPDR Series Trust S&P Biotech |
| Stock Symbol: | XBI |
| Market: | NYSE |
Get XBI Alerts
News, Short Squeeze, Breakout and More Instantly...